The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Medicare for All could expand access to medical interventions—the very goal of biomedical research.

About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 

The American Clinical Laboratory Association claims that scheduled reimbursements for tests are too low and could put small companies out of business.

If made law, the American Health Care Act passed today in the US House would eliminate the Obamacare-funded initiative.